Menu
US
Shop
Request a Quote
Contact Us
US

Cell Lines & Stem Cells

View products & services View resource library

Efficient cell line development to deliver productive endpoints

Our comprehensive suite of cell lines caters to a wide range of applications, spanning from biologics discovery through preclinical development. Designed to seamlessly align with your research and development needs, our cell lines offer the foundation for your scientific breakthroughs.

Choose from a variety of cell lines, including GPCR cell lines, Luciferase-labeled tumor cell lines, Engineered cell lines, Chosource platform, Membrane preparations.

Our cell lines can be used to identify and characterize biomarkers of interest, while addressing specificity and validation challenges through next-generation platforms.

Cell Lines & Stem Cells

Explore our cell lines & stem cells solutions

View all View less
bg-element-listing-page bg-element-listing-page-mobile
Products & Services
Resource Library
Filters
Expand All|Collapse All
Featured category
Resource Type
Sort by: Resource Name A-Z
Resource Name A-Z
Resource Name Z-A
1 - 17 of 17 Resources
Application Note
Application Note
cAMP AlphaScreen assay: a method for the pharmacological characterization and screening of Gαi coupled receptors in whole cells

G protein-coupled receptors (GPCRs) are a large family of transmembrane receptors that are significant drug targets. They function as enzymes that activate G-proteins. GPCRs couple to three main families of Gα subunits: Gαi/o, Gαs, and Gαq. The coupling specificity depends on the GPCR and its cellular environment. Gαs and Gαi subunits operate through the cAMP pathway, either activating or inhibiting adenylate cyclase, which converts ATP to cAMP. In this application note, the AlphaScreen™-based cAMP detection technology has been used to study Gαi-coupled receptors, specifically the 5-hydroxytryptamine-1A (5-HT1A) serotonergic receptor. The note demonstrates the utility of the AlphaScreen-based cAMP Assay kit for the pharmacological characterization and potential high-throughput screening of Gαi-coupled receptors.

Learn More
Application Note
Application Note
cAMP assay provides flexibility and stable pharmacology

G protein-coupled receptors (GPCRs) play a crucial role in various cellular and physiological processes, including cell proliferation, differentiation, neurotransmission, development, and apoptosis. GPCR activity is commonly assessed by measuring levels of intracellular cAMP upon stimulation by agonists. Abnormal GPCR activity is associated with many diseases, including cancer, making GPCRs an important class of pharmaceutical drug targets. Multiple assay formats have been developed to measure the level of cAMP generated, which can determine the pharmacological potency of different agonists and antagonists. The ideal assay is homogeneous, non-radioactive, and allows for sensitive and reproducible detection. AlphaScreen ™ technology provides a quantitative detection of molecules in a homogeneous, no-wash format and can be applied to GPCR research. Download this application note to learn more on the cAMP AlphaScreen assay: Detailed protocol, Data illustrated by graph and tables, Dynamic range description and validation.

Learn More
Flyer
Flyer
CD34+ hematopoietic stem cells: Research with confidence

Learn More
Application Note
Application Note
Characterizing chemokine receptor inhibitors with AlphaLISA SureFire Ultra, Alpha SureFire Ultra Multiplex and LANCE Ultra cAMP assays

The measurement of protein phosphorylation is a useful tool for measuring the modulation of receptor activation by both antibodies and small molecules. CCR7 and CXCR2 receptors, which are expressed in immune cells and are therapeutic targets for disorders like lupus erythematosus, adult leukemia, lymphomas, chronic obstructive pulmonary disease (COPD), and sepsis. AlphaLISA ™ SureFire ® Ultra ™ and Alpha SureFire ® Ultra ™ Multiplex assays are automation-friendly, applicable to both small and large-scale screens, and can assess phosphorylation status in complex matrices. The LANCE Ultra cAMP assay is measures cyclic AMP (cAMP) produced upon modulation of adenylyl cyclase activity by G-protein coupled receptors (GPCRs). This application note demonstrates how the SureFire Ultra and LANCE Ultra cAMP assays can be used for measuring inhibitors to CCR7 and CXCR2 cell surface receptors using a cellular model system where these receptors are overexpressed in CHO cells. The assays were optimized to measure receptor blockage and assayed receptor activity modulation by detecting ERK and AKT phosphorylation status and cAMP modulation. For more details, download the application note!

Learn More
Application Note
Application Note
Functional GPCR Studies Using AlphaScreen cAMP Detection Kit

G protein-coupled receptors (GPCRs) are cell surface transmembrane receptors that activate G-proteins. GPCR activity is often assessed by measuring intracellular cAMP levels upon stimulation by agonists. Since GPCRs are important pharmaceutical drug targets, there’s a high demand for methods to detect and quantify cAMP. The ideal assay is homogenous, non-radioactive, and allows for sensitive and reproducible detection of cAMP. The AlphaScreen™ cAMP assay is one such method. It was evaluated for its ability to detect agonist or antagonist-induced cAMP responses in cells expressing either endogenous or recombinant receptors. Read this application note to access detailed data and results on GPCR studies using AlphaScreen cAMP detection kit.

Learn More
Brochure
Brochure
GPCRs: the pathway to discovery

G protein coupled-receptors (GPCRs) are one of the most intensively studied drug targets, with up to one-third of all marketed therapeutics acting by binding to GPCRs. Therapies that target GPCRs include both agonist and antagonists that are used in the treatment of disease in nearly every major organ system and hold significance in several therapeutic areas, such as cardiovascular diseases, neurosciences, respiratory diseases, metabolic disorders, oncology, and rare diseases. We know the importance of furthering GPCR research - and we answer the call with application notes, white papers, and end-to-end solutions including reagents, instruments, and tools for all aspects of research into today’s most promising drug target. For research use only. Not for use in diagnostic procedures.

Learn More
Application Note
Application Note
Improved deep-tissue imaging with red-shifted luciferase tumor cell lines

The application note demonstrates how our IVISbrite tumor cell lines labeled with red-shifted luciferase (Red F-luc) yields a 100-fold higher signal intensity compared to competitor luciferase labeled cells. The increased brightness of our Red F-luc bioluminescent cells lines enable deeper tissue imaging of tumors. For research use only. Not for use in diagnostic procedures.

Learn More
eBook
eBook
In vivo imaging solutions

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 20,000 peer reviewed articles as proof.

Learn More
FAQ
FAQ
IVISbrite Tumor cell lines and substrates

Learn More
Literature - Publication Review
Literature - Publication Review
Key signaling pathways in liquid cancer: therapeutic targets, screening tools, and future developments

Liquid tumors, which occur in the blood, bone marrow, or lymph nodes, are categorized into three main types of cancer: leukemia, lymphoma, and myeloma. Unlike solid tumors such as carcinomas and sarcomas, these cancers do not form solid masses, leading to different diagnosis and treatment approaches. Leukemia and lymphoma, both forms of blood cancer, affect the body differently. Leukemia primarily impacts the blood and bone marrow, while lymphomas mainly affect the lymph nodes. Significant progress has been made in developing new treatments for both cancers, often targeting the signaling pathways that are constantly activated in specific cancer types. This review highlights some of these signaling pathways and demonstrates how assays based on HTRF and AlphaLISA technologies can be used in the screening and development of new therapies for leukemia and lymphoma treatment.

Learn More
Application Note
Application Note
LANCE Ultra cAMP: a new TR-FRET cAMP assay for Gs - and Gi-coupled receptors.

We have developed a second-generation LANCE® time-resolved fluorescence resonance energy transfer (TR-FRET) immunoassay designed to measure cAMP produced upon modulation of adenylyl cyclase activity by activated GPCRs

Learn More
Application Note
Application Note
Measuring Performance of an Automated and Miniaturized LANCE Ultra cAMP Assay for the Gi-coupled 5-HT1A Receptor- a Comparative Study

In this note we describe the miniaturization of a LANCE Ultra cAMP assay from 384-to 1,536-well plate format for the identification and characterization of agonists and antagonists of a Gi-coupled GPCR.

Learn More
Brochure
Brochure
Radioligand selection guide

Discover a comprehensive collection of GPCR cell lines, membrane preparations, and complementary radioligands designed to drive your GPCR research. Utilize this selection guide to easily identify: Cell lines available for specific receptors Assays that cell lines are validated for Corresponding complementary radioligands and their pharmacological action Learn more about the tools to support your research in this guide!

Learn More
Protocol/SOP
Protocol/SOP
SOP: Cell preparation and instructions for in vivo injection of IVISbrite tumor cells

Learn More
Protocol/SOP
Protocol/SOP
SOP: IVISbrite LNCaP red F-luc tumor cell culture guidelines

Learn More
Protocol/SOP
Protocol/SOP
SOP: IVISbrite tumor cell culture guidelines

Learn More
Flyer
Flyer
The 5 most common mistakes to avoid when culturing IVISbrite tumor cells

Learn More